Evidence map›Paper›PMID 36629157›Full record

ArticleAsian journal of andrology2023

Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.

Antonio Benito Porcaro, Alessandro Tafuri, Andrea Panunzio, Clara Cerrato, Alberto Bianchi, Sebastian Gallina, Stefano Vidiri, Damiano D'Aietti, Emanuele Serafin, Giovanni Mazzucato and 6 more

Open access · goldAbstract read
In one paragraph

Article in Asian journal of andrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Antonio Benito PorcaroDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Alessandro TafuriDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Andrea PanunzioDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Clara CerratoDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Alberto BianchiDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Sebastian GallinaDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Stefano VidiriDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Damiano D'AiettiDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Emanuele SerafinDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Giovanni MazzucatoDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Alessandro PrinciottaDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Davide BrusaDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Matteo BrunelliDepartment of Pathology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Vincenzo PagliaruloDepartment of Urology, Vito Fazzi Hospital, Lecce 73100, Italy.
Maria Angela CerrutoDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Integrated University Hospital of Verona, Verona 37126, Italy.
University of Verona · ITOspedale Vito Fazzi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We tested the association between endogenous testosterone density (ETD; the ratio between endogenous testosterone [ET] and prostate volume) and prostate cancer (PCa) aggressiveness in very favorable low- and intermediate-risk PCa patients who underwent radical prostatectomy (RP). Only patients with prostate-specific antigen (PSA) within 10 ng ml -1 , clinical stage T1c, and International Society of Urological Pathology (ISUP) grade group 1 or 2 were included. Preoperative ET levels up to 350 ng dl -1 were classified as abnormal. Tumor quantitation density factors were evaluated as the ratio between percentage of biopsy-positive cores and prostate volume (biopsy-positive cores density, BPCD) and the ratio between percentage of cancer invasion at final pathology and prostate weight (tumor load density, TLD). Disease upgrading was coded as ISUP grade group >2, and progression as recurrence (biochemical and/or local and/or distant). Risk associations were evaluated by multivariable Cox and logistic regression models. Of 320 patients, 151 (47.2%) had intermediate-risk PCa. ET (median: 402.3 ng dl -1 ) resulted abnormal in 111 (34.7%) cases (median ETD: 9.8 ng dl -1 ml -1 ). Upgrading and progression occurred in 109 (34.1%) and 32 (10.6%) cases, respectively. Progression was predicted by ISUP grade group 2 (hazard ratio [HR]: 2.290; P = 0.029) and upgrading (HR: 3.098; P = 0.003), which was associated with ISUP grade group 2 (odds ratio [OR]: 1.785; P = 0.017) and TLD above the median (OR: 2.261; P = 0.001). After adjustment for PSA density and body mass index (BMI), ETD above the median was positively associated with BPCD (OR: 3.404; P < 0.001) and TLD (OR: 5.238; P < 0.001). Notably, subjects with abnormal ET were more likely to have higher BPCD (OR: 5.566; P = 0.002), as well as TLD (OR: 14.998; P = 0.016). Independently by routinely evaluated factors, as ETD increased, BPCD and TLD increased, but increments were higher for abnormal ET levels. In very favorable cohorts, ETD may further stratify the risk of aggressive PCa.

Indexed as

Disease ProgressionProstatectomyProstatic NeoplasmsTestosteroneAgedHumansMaleMiddle AgedNeoplasm GradingProstateProstate-Specific AntigenRetrospective StudiesRisk FactorsProstate-Specific AntigenTestosterone

Identifiers

PMID36629157
PMCPMC10521947
OpenAlexW4313644878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.